1. Home
  2. PHAR vs ETD Comparison

PHAR vs ETD Comparison

Compare PHAR & ETD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAR
  • ETD
  • Stock Information
  • Founded
  • PHAR 1988
  • ETD 1932
  • Country
  • PHAR Netherlands
  • ETD United States
  • Employees
  • PHAR N/A
  • ETD N/A
  • Industry
  • PHAR Biotechnology: Pharmaceutical Preparations
  • ETD Home Furnishings
  • Sector
  • PHAR Health Care
  • ETD Consumer Discretionary
  • Exchange
  • PHAR Nasdaq
  • ETD Nasdaq
  • Market Cap
  • PHAR 718.1M
  • ETD 700.3M
  • IPO Year
  • PHAR N/A
  • ETD 1993
  • Fundamental
  • Price
  • PHAR $10.45
  • ETD $27.37
  • Analyst Decision
  • PHAR Strong Buy
  • ETD Hold
  • Analyst Count
  • PHAR 3
  • ETD 2
  • Target Price
  • PHAR $30.00
  • ETD $30.00
  • AVG Volume (30 Days)
  • PHAR 2.6K
  • ETD 228.8K
  • Earning Date
  • PHAR 07-31-2025
  • ETD 07-30-2025
  • Dividend Yield
  • PHAR N/A
  • ETD 5.70%
  • EPS Growth
  • PHAR N/A
  • ETD N/A
  • EPS
  • PHAR N/A
  • ETD 2.25
  • Revenue
  • PHAR $320,708,000.00
  • ETD $622,924,000.00
  • Revenue This Year
  • PHAR $13.31
  • ETD N/A
  • Revenue Next Year
  • PHAR $7.68
  • ETD $0.96
  • P/E Ratio
  • PHAR N/A
  • ETD $12.15
  • Revenue Growth
  • PHAR 24.13
  • ETD N/A
  • 52 Week Low
  • PHAR $6.65
  • ETD $24.55
  • 52 Week High
  • PHAR $12.61
  • ETD $35.62
  • Technical
  • Relative Strength Index (RSI)
  • PHAR 47.51
  • ETD 55.24
  • Support Level
  • PHAR $10.41
  • ETD $26.65
  • Resistance Level
  • PHAR $11.50
  • ETD $27.54
  • Average True Range (ATR)
  • PHAR 0.32
  • ETD 0.56
  • MACD
  • PHAR -0.17
  • ETD 0.14
  • Stochastic Oscillator
  • PHAR 2.26
  • ETD 91.90

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About ETD Ethan Allen Interiors Inc.

Ethan Allen Interiors Inc through its subsidiaries, operates as an interior design company, and a manufacturer and retailer in the home furnishings marketplace. Its product offerings include fabric chairs, beds, wallpapers, desks, and dining tables among others. The company's reportable segments are; Wholesale and Retail. The Wholesale segment is principally involved in the development of the Ethan Allen brand and encompasses all aspects of design, manufacturing, sourcing, marketing, sale, and distribution of home furnishings and accents. The Retail segment which generates maximum revenue, sells home furnishings and accents to clients through company-operated design centers. Geographically, it derives key revenue from the United States and the rest from other regions.

Share on Social Networks: